

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/286768 A1

(51) International Patent Classification:

C07D 241/36 (2006.01) A61P 25/00 (2006.01)
C07D 405/12 (2006.01) A61K 31/498 (2006.01)

(21) International Application Number:

PCT/JP2022/027396

(22) International Filing Date:

12 July 2022 (12.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2021-115550 13 July 2021 (13.07.2021) JP

(71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
[JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo,
1018535 (JP).

(72) Inventors: SHINOHARA, Tomoichi; c/o OTSUKA
PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-
ku, Osaka-shi, Osaka, 5400021 (JP). NISHIYAMA,
Tsuyoshi; c/o OTSUKA PHARMACEUTICAL CO.,
LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka,
5400021 (JP).

(74) Agent: YAMAO, Norihito et al.; AOYAMA & PART-
NERS, Osaka Umeda Twin Towers North, 8-1, Kaku-
da-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HYDROGENATED QUINOXALINES



[I]

(57) Abstract: Provided is a therapeutic agent for ADHD having an efficacy comparable to that of central nervous system stimulants and the same low risk of drug dependence and abuse as existing non-central nervous system stimulants, more particularly a compound represented by formula [I]: wherein each symbol is as defined in the description, or a salt thereof.

WO 2023/286768 A1